Neurotech International (ASX:NTI)
ASX announcement history & article coverage
Transparent by design.
Announcments by Neurotech International (ASX:NTI) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Initial Director's Interest Notice
Notification of cessation of securities - NTI
Board and Management Changes
Final Director's Interest Notice
Appendix 4G and Corporate Governance Statement
Appendix 4E & Annual Report to shareholders
Neurotech advances Phase 3 ASD trial, cuts loss 38%, raises $3.75M
Appointment of Executive Chairman
Becoming a substantial holder
Secondary Trading Notice
Application for quotation of securities - NTI
Proposed issue of securities - NTI
Proposed issue of securities - NTI
Receipt of Binding Commitments for $4.5m Placement
Neurotech raises $4.5 million placement to fund Phase III ASD trial
Quarterly Activities/Appendix 4C Cash Flow Report
Neurotech advances NTI164 with FDA IND clearance, patent progress, and expanded prescriber program
Trading Halt
NTI164 Phase II/III Autism Data Accepted for Publication
Secondary Trading Notice
Application for quotation of securities - NTI
Neurotech secures $3.15 million R&D tax incentive loan
Neurotech secures $3.15 million R&D tax incentive loan for Phase III ASD trials
US FDA clears IND for NTI164
US FDA clears IND for Neurotech's NTI164, advancing global clinical and commercial strategy
Notification regarding unquoted securities - NTI
Proposed issue of securities - NTI
NTI secures Notices of Allowance for US patent applications
Neurotech secures US patent allowances for NTI164, strengthening IP protection through 2042
Notification of cessation of securities - NTI